|
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action/Capital Increase Korneuburg, Austria, 27. November 2024 - As Marinomed Biotech AG (the "Company" or "Marinomed") announced in its ad hoc announcement dated 18 September 2024 regarding the first cash capital increase of 154,053 new shares (the "First Cash Capital Increase"), the Company is negotiating with investors regarding a possible second cash capital increase, which would be carried out in accordance with the authorisation to exclude the subscription rights of existing shareholders (the "Second Capital Increase"). Marinomed is currently continuing to discuss with several investors such a Second Capital Increase, although no agreements or board resolutions have yet been reached.
The Company's Management Board has resolved today to publish a report on the intended exclusion of subscription rights of existing shareholders for a possible cash capital increase of up to EUR 154,053 by issuing up to 154,053 new no-par value bearer shares against cash contribution (the "Report"). The Report on the exclusion of subscription rights is to be published as soon as possible on the electronic announcement and information platform of the Federal Government of Austria ("EVI"). With the publication of the Report, the Company's Management Board ensures that, in the event of a short-term financing requirement of the Company, the Company's Management Board is legally in a position to resolve on a new cash capital increase from the authorised capital 2024 in accordance with § 5 para (6) of the Company's Articles of Association (the "Authorised Capital 2024") at short notice with the approval of the Supervisory Board. The background to this is that a report on the planned exclusion of subscription rights must be published at least two weeks prior to the required Supervisory Board resolution. Against the background of the cash ratio to be deposited in accordance with the adopted restructuring plan, the Company is creating the prerequisite for being able to raise necessary equity at short notice and not having to wait for the two-week period to expire in this case. The actual implementation of a possible Second Capital Increase remains dependent on the outcome of negotiations with investors, the conclusion of the respective transaction documents and the adoption of resolutions by the Company's Management Board and Supervisory Board. In addition, the restructuring proceedings (still needed for a Second Capital Increase) require the approval by the restructuring administrator. +++ End of ad-hoc announcement +++ End of Inside Information
27-Nov-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com |
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
| EQS News ID: | 2039559 |
| End of Announcement | EQS News Service |
|
|
2039559 27-Nov-2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
